210 related articles for article (PubMed ID: 26209365)
21. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
22. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
24. Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death.
Wang X; Wei S; Zhao Y; Shi C; Liu P; Zhang C; Lei Y; Zhang B; Bai B; Huang Y; Zhang H
Cancer Lett; 2017 Jan; 385():128-136. PubMed ID: 27810405
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.
Bracker TU; Sommer A; Fichtner I; Faus H; Haendler B; Hess-Stumpp H
Int J Oncol; 2009 Oct; 35(4):909-20. PubMed ID: 19724929
[TBL] [Abstract][Full Text] [Related]
26. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
27. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
28. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
[TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
35. Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner.
Li H; Xu X; Zhang Y; Tang X; Li W
Eur J Pharmacol; 2020 Dec; 888():173575. PubMed ID: 32950498
[TBL] [Abstract][Full Text] [Related]
36. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
37. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
38. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
39. Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Hassanvand F; Mohammadi T; Ayoubzadeh N; Tavakoli A; Hassanzadeh N; Sanikhani NS; Azimi AI; Mirzaei HR; Khodamoradi M; Goudarzi KA; Pourghadamyari H; Zaimy MA
J Cancer Res Ther; 2020; 16(6):1412-1418. PubMed ID: 33342806
[TBL] [Abstract][Full Text] [Related]
40. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
